Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
Global Targeted DNA & RNA Sequencing market size was valued at USD 3.25 billion in 2024 and is projected to reach USD 7.12 billion by 2031, exhibiting a CAGR of 13.4% during the forecast period. While North America currently dominates with over 40% market share, Asia-Pacific is expected to witness the fastest growth due to increasing healthcare investments in emerging economies like China and India.
Targeted DNA & RNA sequencing is a next-generation sequencing approach that focuses on specific genomic regions or transcripts of interest, offering higher sensitivity and cost-efficiency compared to whole-genome methods. This technology enables researchers to analyze coding regions (exomes), gene panels, or custom target sets with high precision, facilitating applications in cancer genomics, inherited disease screening, and pharmacogenomics. The methodology includes both DNA-based approaches for mutation detection and RNA-based techniques for gene expression profiling.
The market growth is being driven by several key factors: rising demand for personalized medicine, increasing prevalence of chronic diseases requiring genomic analysis, and technological advancements in sequencing platforms. Major players like Illumina and Thermo Fisher Scientific have recently launched enhanced target enrichment kits and automated workflows, further accelerating adoption. Additionally, the integration of artificial intelligence for data analysis and declining sequencing costs per sample are making these technologies more accessible to clinical laboratories and research institutions worldwide.
Increasing Demand for Precision Medicine
The growing adoption of precision medicine approaches is driving demand for targeted DNA & RNA sequencing. Clinicians require highly accurate genetic data to develop personalized treatment plans, with the global precision medicine market projected to reach $132 billion by 2026.
Advancements in Oncology Diagnostics
Targeted sequencing plays a crucial role in cancer diagnostics, with over 75% of oncology research now utilizing some form of targeted sequencing panels. The ability to focus on specific cancer-related mutations has improved both the speed and cost-effectiveness of diagnosis.
Technological innovations like hybrid capture and amplicon-based sequencing are reducing costs while improving accuracy
Clinical applications continue to expand, with over 200 FDA-approved targeted sequencing panels now available for various genetic conditions.
MARKET CHALLENGES
Data Interpretation Complexity
The growing volume of sequencing data presents significant interpretation challenges. Laboratories require specialized bioinformatics expertise, and the shortage of qualified personnel remains a bottleneck for market expansion.
Other Challenges
Regulatory Hurdles
Navigating varying international regulations for clinical-grade sequencing tests increases time-to-market and compliance costs for manufacturers.
Reimbursement Limitations
Inconsistent insurance coverage for targeted sequencing tests creates barriers to widespread clinical adoption, particularly in developing healthcare systems.
High Initial Investment Costs
The capital expenditure required for targeted sequencing equipment remains substantial, with complete laboratory setups often exceeding $500,000. This creates significant barriers for smaller diagnostic centers and research facilities.
Ongoing operational costs for reagents, quality controls, and personnel training further limit market penetration in cost-sensitive regions.
Expansion in Emerging Markets
Developing economies represent significant growth potential as healthcare infrastructure improves. The Asia-Pacific targeted sequencing market is projected to grow at 18% CAGR through 2025, driven by increasing cancer prevalence and government initiatives.
Point-of-Care Applications
Miniaturization of sequencing technologies opens opportunities for decentralized testing. Emerging portable sequencing solutions could transform rapid diagnostics in critical care settings and remote locations.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
DNA-based Targeted Sequencing maintains dominance due to its widespread adoption in clinical diagnostics and genetic research. The technology provides comprehensive mutation detection capabilities, while RNA-based Targeted Sequencing is gaining traction for its ability to provide quantitative expression data and identify transcript variants with high specificity. |
| By Application |
|
Human Biomedical Research drives the largest application segment, propelled by personalized medicine initiatives and cancer genomics. Drug Discovery applications are growing rapidly as pharmaceutical companies leverage targeted sequencing for biomarker identification. The technology also finds increasing utility in agricultural genomics through Plant & Animal Sciences applications. |
| By End User |
|
Academic & Research Institutes remain the primary end users, benefiting from continuous technology innovation and funding for genomic studies. Pharmaceutical & Biotech Companies are adopting targeted sequencing at an accelerated pace for precision medicine development, while Clinical Laboratories implement these technologies for routine diagnostic applications in oncology and rare diseases. |
| By Technology |
|
Hybridization Capture techniques lead the technology segment due to their flexibility in targeting large genomic regions and compatibility with multiple sample types. Amplicon-based methods are valued for their simplicity and cost-effectiveness in smaller target panels, while Molecular Inversion Probes offer advantages in highly multiplexed detection of rare variants. |
| By Target Size |
|
Medium Panels represent the most balanced solution between comprehensiveness and cost-efficiency, covering clinically relevant gene sets without unnecessary sequencing overhead. Small Panels remain popular for focused clinical applications, while Large Panels are increasingly adopted for exploratory research in complex diseases where broader genomic coverage provides better insights. |
Illumina Dominates Targeted Sequencing Market with ~35% Revenue Share
Illumina, Inc. maintains market leadership in targeted DNA & RNA sequencing with its comprehensive NGS platforms and library preparation solutions. The global competitive landscape remains concentrated, with the top five players (Illumina, Thermo Fisher, Roche, Agilent, and QIAGEN) collectively holding approximately 65% revenue share in 2024. Strategic acquisitions and partnerships have intensified competition, particularly in oncology and rare disease research applications. Companies are investing heavily in workflow automation and data analysis integration to differentiate their offerings.
Emerging players like Oxford Nanopore Technologies and Pacific Biosciences are gaining traction through innovative long-read sequencing technologies. Specialized providers such as GATC Biotech and DNASTAR focus on niche applications including agricultural genomics and viral surveillance. The Asia-Pacific region shows expanding presence of BGI and Macrogen, leveraging cost advantages in high-throughput sequencing services. Market consolidation continues as mid-sized firms face pricing pressures from dominant players' economies of scale.
List of Key Targeted DNA & RNA Sequencing Companies ProfiledAgilent Technologies
GATC Biotech Ag
Oxford Nanopore Technologies
DNASTAR Inc.
BGI
Perkin Elmer, Inc.
Bio-Rad Laboratories, Inc.
Integrated DNA Technologies, Inc.
Macrogen, Inc.
PierianDx
The global Targeted DNA & RNA Sequencing market is experiencing robust expansion, currently valued at $2.4 billion in 2024 and projected to reach $5.8 billion by 2031, growing at a CAGR of 12.8%. This growth is primarily driven by increasing applications in clinical diagnostics and drug discovery, where targeted sequencing offers cost-effective solutions compared to whole genome approaches. The U.S. accounts for 38% of current market share, while China emerges as the fastest-growing region with 18% CAGR through 2031.
Other TrendsApplication Segment Growth
Human biomedical research dominates application segments with 42% market share, while drug discovery applications are projected to grow at 15.3% CAGR. The technology's ability to focus on specific genomic regions and transcripts enables more efficient biomarker discovery and targeted therapy development, particularly in oncology and rare disease research.
Technological Advancements in Sequencing PlatformsMajor players like Illumina and Thermo Fisher Scientific continue to innovate with higher throughput and lower-cost platforms. The DNA-based targeted sequencing segment currently holds 65% market share, while RNA-based sequencing grows faster at 14.5% CAGR. Recent developments in nanopore sequencing and single-cell analysis are creating new opportunities in transcriptome profiling and spatial genomics.
Competitive Landscape Consolidation
The top five companies control 58% of the global market, with Illumina maintaining leadership at 27% share. Strategic acquisitions and partnerships are accelerating, particularly in cancer diagnostics and liquid biopsy applications. Emerging players focusing on niche applications like agricultural genomics are gaining traction in regional markets.
Regional Market DevelopmentsNorth America remains the largest market at $920 million in 2024, while Asia-Pacific shows strongest growth potential with China and India investing heavily in genomic research infrastructure. Europe follows with steady growth in clinical adoption, particularly in Germany and the UK where reimbursement policies increasingly cover targeted sequencing for oncology applications.
Regional Analysis: Targeted DNA & RNA Sequencing MarketEurope
Europe maintains strong growth in targeted sequencing through national genomics initiatives like the UK's 100,000 Genomes Project. The region shows particular strength in NIPT applications and rare disease diagnostics. Germany leads in adoption of CE-IVD marked targeted panels, while French hospitals implement sequencing in standard oncology care pathways. Data privacy regulations influence sequencing service models. Cross-border collaboration through the European Reference Networks expands access to specialized testing. Scandinavia excels in population-scale sequencing projects utilizing targeted approaches for cost efficiency.
Asia-Pacific
Asia-Pacific emerges as the fastest-growing region fueled by China's precision medicine initiative and India's expanding diagnostic market. China dominates APAC with massive genomics investments and domestic sequencing platform development. Japan leads in cancer panel utilization, while Australia focuses on translational research applications. Southeast Asian countries show growing adoption in private clinical labs despite infrastructure limitations. Regional growth is propelled by government-backed population genomics projects and increasing focus on hereditary disease screening using targeted methods.
Latin America
Latin America experiences gradual uptake focused on major urban centers with high-end private hospitals. Brazil accounts for nearly half of regional demand, with oncology being the primary application. Argentina shows increasing research activity in agricultural genomics using targeted approaches. Limited reimbursement options constrain broader clinical adoption outside self-pay markets. Regional initiatives like Argentina's PoblAr project stimulate sequencing infrastructure development, though targeted panel availability remains restricted to imported products.
Middle East & Africa
The Middle East demonstrates targeted sequencing adoption in prenatal diagnostics and hereditary disease screening, particularly in Gulf Cooperation Council countries. UAE and Saudi Arabia invest heavily in genomics infrastructure to reduce overseas testing dependence. Africa sees nascent growth through research partnerships like H3Africa, but faces severe infrastructure limitations. South Africa leads in clinical applications, with targeted panels primarily used for HIV and TB research. Local production of targeted sequencing reagents remains minimal across the region.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biotechnology and pharmaceutical companies
Clinical research organizations
Diagnostic laboratories and hospitals
Academic and research institutions
Investors and policy makers
-> Global Targeted DNA & RNA Sequencing market was valued at USD 3.25 billion in 2024 and is projected to reach USD 7.12 billion by 2031.
Which key companies operate in Global Targeted DNA & RNA Sequencing Market?
-> Key players include Illumina, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, and QIAGEN, among others.
-> Key growth drivers include rising demand for personalized medicine, increasing prevalence of chronic diseases, and technological advancements.
-> North America currently dominates with over 40% market share, while Asia-Pacific is expected to witness the fastest growth.
-> Emerging trends include enhanced target enrichment kits, automated workflows, and integration of artificial intelligence for data analysis.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates